Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spruce BiosciencesSPRB -1.25%40 Forward PE Ratio is 0.00 as of Aug. 02, 2026. GuruFocus rates SPRB with a GF Score™ of 40/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 354 Biotechnology companies, Spruce Biosciences ranks worse than 282485.59% on this metric.
Spruce Biosciences (NAS:SPRB) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Spruce Biosciences Forward PE Ratio Related Terms
Spruce Biosciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Spruce Biosciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences Forward PE Ratio Chart
Spruce Biosciences Annual Data
Trend
Forward PE Ratio
Spruce Biosciences Quarterly Data
Forward PE Ratio
SPRB vs VXRT, VTVT, ENGN: Forward PE Ratio Comparison
For the Biotechnology subindustry, Spruce Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Spruce Biosciences (SPRB) has a Forward PE Ratio of 0.00 as of Aug. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Spruce Biosciences and its competitors. According to the industry distribution chart, Spruce Biosciences ranks #999999 out of 354 companies in the Biotechnology industry.
Is Spruce Biosciences' Forward PE Ratio too high?
Spruce Biosciences' current Forward PE Ratio is 0.00. Based on the distribution chart, Spruce Biosciences ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spruce Biosciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' Forward PE Ratio compare to VXRT and VTVT?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #999999 out of 354 companies for Forward PE Ratio. This places Spruce Biosciences in the lower half of its industry. The industry median Forward PE Ratio is 22.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.29, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Spruce Biosciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $42.83 — trading 949.8% above its estimated fair value. The current Forward PE Ratio is 0.00. Spruce Biosciences' overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Forward PE Ratio is 0.00 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $42.83 is trading 949.8% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
Forward PE Ratio: 0.00
GF Value™: $4.08 vs. price of $42.83 (949.8% above fair value)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
40GF Score
Get the complete analysis for SPRB
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
